TrialThe oncologist2023

Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial.

James Larkin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.